ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Diisopropylethylamine → (R)-1-methoxy-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-oxopropan-2-yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate

HRID 2099837
印刷

反応式

HRID 2099837 の反応式
[C:1](=O)([O:27]C1C=CC([N+]([O-])=O)=CC=1)[O:2][CH:3]([C:23]([O:25][CH3:26])=[O:24])[CH2:4][C:5]1[CH:13]=[C:12]([CH3:14])[C:11]2[C:7](=[CH:8][N:9]([CH2:15][O:16][CH2:17][CH2:18][Si:19]([CH3:22])([CH3:21])[CH3:20])[N:10]=2)[CH:6]=1.Cl.[NH:39]1[CH2:44][CH2:43][CH:42]([C:45]2[C:46](=[O:55])[NH:47][C:48]3[C:53]([CH:54]=2)=[CH:52][CH:51]=[CH:50][CH:49]=3)[CH2:41][CH2:40]1.C(N(C(C)C)CC)(C)C>>[O:55]=[C:46]1[C:45]([CH:42]2[CH2:43][CH2:44][N:39]([C:1]([O:2][C@H:3]([CH2:4][C:5]3[CH:13]=[C:12]([CH3:14])[C:11]4[C:7](=[CH:8][N:9]([CH2:15][O:16][CH2:17][CH2:18][Si:19]([CH3:21])([CH3:22])[CH3:20])[N:10]=4)[CH:6]=3)[C:23]([O:25][CH3:26])=[O:24])=[O:27])[CH2:40][CH2:41]2)=[CH:54][C:53]2[C:48](=[CH:49][CH:50]=[CH:51][CH:52]=2)[NH:47]1
参加物実験手順後処理出典と根拠反応ノート

参加物

4

反応物 3

HCID 81531DiisopropylethylamineHCID 577946441-(methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-indazol-5-yl)ethyl 4-nitrophenyl carbonateHCID 673176623-piperidin-4-yl-1H-quinolin-2-one;hydrochloride

生成物 1

HCID 57794717(R)-1-methoxy-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-oxopropan-2-yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate収率 30%

実験手順

To a solution of 1-(methoxycarbonyl)-2-(2-((2-(trimethylsilyl)ethoxy)methyl)-7-methyl-2H-indazol-5-yl)ethyl 4-nitrophenyl carbonate (0.859 mmol) was added 3-(piperidin-4-yl)quinolin-2(1H)-one-hydrochloride (682 mg, 2.58 mmol), in one portion, followed by dropwise addition of diisopropylethylamine (0.37 mL, 2.15 mmol) at room temperature. The resulting yellow suspension was stirred at room temperature overnight. The mixture was extracted with ethyl acetate (2×2 mL) and the organic phase was washed with brine and dried over sodium sulfate. The crude product was purified using preparative HPLC to afford (R)-1-methoxy-3-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)-1-oxopropan-2-yl 4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxylate (157 mg, 30%). Mass spec. 619.24 (MH+). 1H-NMR (CDCl3, 400 MHz) δ 8.0 (s, 1H), 7.53 (br s, 2H), 7.47-7.43 (m, 1H), 7.34-7.31 (m, 1H), 7.21-7.18 (m, 1H), 6.96 (s, 1H), 5.7 (s, 2H), 5.23 (dd, J=8.6, 4.6 Hz, 1H), 4.28 (br s, 2H), 3.74 (s, 3H), 3.61 (m, 2H), 3.13 (m, 3H), 2.93 (m, 2H), 2.59 (s, 3H), 1.94 (m, 2H), 0.92 (m, 2H), −0.064 (s, 9H).

後処理

  1. extractionThe mixture was extracted with ethyl acetate (2×2 mL)
  2. washthe organic phase was washed with brine
  3. dry with materialdried over sodium sulfate
  4. customThe crude product was purified

出典と根拠

ORDレコード
ord-97b7baeb212f40fb8f952c762c8b6dfb
出典データセット
uspto-grants-2009_08
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07569578B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート